Mitsushige Nakao
Otsu, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome.
Journal: British journal of haematology
Published: February 02, 2026
Clinical issues and perspectives in diffuse large B-cell lymphoma based on 15 years of clinical studies by the Kyoto Hematology Clinical Research Group (KOTOSG)
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: April 02, 2025
Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.
Journal: Leukemia & lymphoma
Published: March 26, 2025
The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma.
Journal: International journal of clinical oncology
Published: November 24, 2024
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.
Journal: Leukemia & lymphoma
Published: February 11, 2022
Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective study.
Journal: Cancer medicine
Published: January 18, 2022
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.
Journal: International journal of hematology
Published: October 01, 2021
Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
Journal: Cancer reports (Hoboken, N.J.)
Published: February 21, 2021
Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma.
Journal: Leukemia & lymphoma
Published: August 28, 2020
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Journal: International journal of hematology
Published: November 27, 2018
Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients.
Journal: International journal of hematology
Published: October 04, 2018
Last Updated: 09/26/2026